Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use within human health and healthcare

May 2017

What is this guideline about and who is it for?

Purpose of this guideline

The purpose of this guideline is to provide good practice recommendations on systems and processes for the effective use of antimicrobials.

Audience for this guideline

- All healthcare providers (a term used to define the wider care team of hospital staff [including microbiologists and infection control staff], nurses, midwives, GPs, dentists, podiatrists, pharmacists, community nurses & case managers [including those staff working in out-of-hours services], domiciliary care workers and care home staff [registered nurses and carers working in care homes], social workers and case managers).
- Organisations funding, providing or supporting the provision of care (for example, national or professional bodies, the Ministry of Health (MoH), PHARMAC, Accident Compensation Corporation (ACC), Health Quality & Safety Commission (HSQC), statutory Medical Officers of Health, District Health Boards, Primary Health Organisations, Rest Homes, Midwifes, Pharmacists, Private Health Insurance Companies, Private Hospital Groups).
- Adults, young people and children (including neonates) using antimicrobials or those caring for these groups. This includes people and organisations involved with the prescribing and management of antimicrobials in all healthcare settings.
It is anticipated that the MoH, District Health Boards (DHBs) and all healthcare providers will need to work together to ensure that patients benefit from the good practice recommendations in this guideline.

**Scope of this guideline**

The guideline covers the effective use of antimicrobials as part of all publicly and privately funded human healthcare provided throughout New Zealand.

The guideline does not cover:

- specific clinical conditions (although some evidence identified included patients with a specific infection such as community acquired pneumonia)
- named medicines
- public health awareness of antimicrobial resistance
- research into new antimicrobials
- immunisation and vaccination
- antimicrobial household cleaning products
- antimicrobial use in animals and plants, including veterinary/animal health, agricultural/aquaculture/horticultural
- hand hygiene, decolonisation and infection prevention and control measures
- medicines adherence, except where there are specific issues for all healthcare providers to address relating to antimicrobials
- access to medicines, including local decision-making for medicines not included on local formularies
- medicines shortages, including supply issues and discontinued medicines
- prescription charges
- waste medicines
- Identification of antibiotic currently being overused in human health care.

- Introduction of funding or prescribing restrictions on the use of antibiotics.
- International treaties, rules and governance.
In the New Zealand setting, many of these issues are extensively discussed elsewhere (including in the New Zealand National Action Plan on Antimicrobial Resistance).

All NICE guidelines are developed in accordance with the NICE equality scheme.

**Person-centred care**

This guideline offers best practice advice on the effective use of antimicrobial medicines.

Patients and health professionals have rights and responsibilities as set out in the [Code of Health and Disability Services Consumers Rights](https://www.healthondemand.co.nz/publications/code-of-health-and-disability-services-consumers-rights). Treatment and care should take into account individual needs and preferences. Patients should have the opportunity to make informed decisions about their care and treatment, in partnership with their health professionals. If the person is under 16, their family/whānau or carers should also be given information and support to help the child or young person to make decisions about their treatment. If it is clear that the child or young person fully understands the treatment and does not want their family/whānau or carers to be involved, they can give their own consent. Health professionals should follow the advice on consent provided by the [Health and Disability Commissioner](https://www.healthcommissioner.govt.nz) and [Ministry of Health](https://www.health.govt.nz). If a person does not have capacity to make decisions, all healthcare providers should follow the code of practice outlined by the [Health and Disability Commissioner](https://www.healthcommissioner.govt.nz) and [Ministry of Health](https://www.health.govt.nz). All health professionals should follow the recommendations in the [Code of Health and Disability Services Consumers’ Rights](https://www.healthcommissioner.govt.nz/publications/code-of-health-and-disability-services-consumers-rights). In addition, all healthcare providers working with people using adult mental health services should follow the recommendations in the [Code of Health and Disability Services Consumers’ Rights](https://www.healthcommissioner.govt.nz/publications/code-of-health-and-disability-services-consumers-rights) and [Consent in Child and Youth Health: Information for Practitioners](https://www.healthcommissioner.govt.nz/publications/consent-in-child-and-youth-health-information-for-practitioners). Adult and paediatric healthcare teams should work jointly to
provide assessment and services to young people and diagnosis and management should be reviewed throughout the transition process. There should be clarity about who is the lead clinician to ensure continuity of care.

1 Recommendations

The following guidance is based on the best available evidence. The full guideline gives details of the methods and the evidence used to develop the guidance.

The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation). See about this guideline for details.

Terms used in this guideline

Antimicrobial stewardship
The term ‘antimicrobial stewardship’ is defined as ‘an organisational or healthcare-system-wide approach to promoting and monitoring judicious use of antimicrobials to preserve their future effectiveness’.

Antimicrobial resistance
The term ‘antimicrobial resistance’ is defined as the ‘loss of effectiveness of any anti-infective medicine, including antiviral, antifungal, antibacterial and antiparasitic medicines’.

Antimicrobials and antimicrobial medicines
The term ‘antimicrobials’ and ‘antimicrobial medicines' includes all anti-infective therapies, (antiviral, antifungal, antibacterial and antiparasitic medicines) and all formulations (oral, parenteral and topical agents).

Organisations
The term ‘organisations’ (also known as the ‘service’) is used to include all funders (including MoH, District Health Boards, PHARMAC, Accident Compensation Corporation) and providers (hospitals, Primary Health Organisations, GPs, out-of-hours services, dentists and other community
based providers) of healthcare services, unless specified otherwise. Occasionally, in order to make a recommendation more specific to the intended care setting, the setting is specified; for example, the recommendation will state 'hospital'.

**Healthcare Providers**

The term healthcare providers is used to define the wider care team, including but not limited to, case managers, care coordinators, GPs, hospital doctors, microbiologists, midwives, pharmacists, nurses and social workers.

### 1.1 *All antimicrobials*

**Recommendations for organisations**

**Antimicrobial stewardship programmes**

1.1.1 The Ministry of Health should ensure that [antimicrobial stewardship](#) operates across all care settings as part of an antimicrobial stewardship programme.

1.1.2 The Ministry of Health and PHARMAC should establish a New Zealand antimicrobial stewardship committee (NZAMSC) which will provide national leadership and take responsibility for fostering antimicrobial stewardship across all healthcare settings.

1.1.3 The NZAMSC should facilitate the provision of the following antimicrobial stewardship activities throughout New Zealand:

- monitoring and evaluating antimicrobial prescribing and how this relates to local resistance patterns
- providing regular feedback to individual prescribers in all care settings about:
  - their antimicrobial prescribing, for example, by using professional regulatory numbers for prescribing as well as prescriber (cost centre) codes
  - patient safety incidents related to antimicrobial use, including hospital admissions for potentially avoidable life-threatening
infections, infections with *Clostridium difficile* or adverse drug reactions such as anaphylaxis

- providing education and training to all healthcare providers about antimicrobial stewardship and antimicrobial resistance
- integrating audit into existing quality improvement programmes.

1.1.4 On advice of the NZAMSC, the Ministry of Health should ensure that roles, responsibilities and accountabilities are clearly defined within an antimicrobial stewardship programme.

1.1.5 On the advice of the NZAMSC, the Ministry of Health should involve lead healthcare providers in establishing processes for developing, reviewing, updating and implementing local antimicrobial guidelines in line with national guidance and informed by local prescribing data and resistance patterns.

1.1.6 On the advice of the NZAMSC, the Ministry of Health should consider developing systems and processes for providing regular updates (at least every year) to individual prescribers and prescribing leads on:

- individual prescribing benchmarked against local and national antimicrobial prescribing rates and trends
- local and national antimicrobial resistance rates and trends
- patient safety incidents related to antimicrobial use, including hospital admissions for potentially avoidable life-threatening infections, infections with *C. difficile* or adverse drug reactions such as anaphylaxis.

1.1.7 On the advice of the NZAMSC, the Ministry of Health should consider developing systems and processes for identifying and reviewing whether hospital admissions are linked to previous prescribing decisions in patients with potentially avoidable infections (for example, rheumatic fever, *Escherichia coli*)
bacteraemias, mastoiditis, pyelonephritis, empyema, quinsy or brain abscess).

**Antimicrobial stewardship teams**

1.1.8 Each District Health Board (DHB), if necessary through regional collaboration, should establish antimicrobial stewardship team (DHBAMST) and should ensure that the team includes the relevant competencies (including an antimicrobial pharmacist, a medical microbiologist and, a primary care representative) and can co-opt additional members depending on the care setting and the antimicrobial issue being considered.

1.1.9 The NZAMSC and the DHBAMSTs should develop processes that promote antimicrobial stewardship and allocate resources, to:

- review prescribing and resistance data and identify ways of feeding this information back to prescribers in all care settings
- promote education for prescribers in all care settings
- assist the local formulary decision-making group with recommendations about new antimicrobials
- update local formulary and prescribing guidance
- work with prescribers to explore the reasons for very high, increasing or very low volumes of antimicrobial prescribing, or use of antimicrobials not recommended in local (where available) or national guidelines
- provide feedback and advice to prescribers who prescribe antimicrobials outside of local guidelines when it is not justified.

**Antimicrobial stewardship interventions**

1.1.10 The NZAMSC and the DHBAMSTs should consider using the following antimicrobial stewardship interventions:

- review of prescribing by antimicrobial stewardship teams to explore the reasons for increasing, very high or very low
volumes of antimicrobial prescribing, or use of antimicrobials not recommended in local (where available) or national guidelines
- promotion of antimicrobials recommended in local (where available) or national guidelines
- IT or decision support systems
- education-based programmes for all healthcare providers, (for example, academic detailing, clinical education or educational outreach).

1.1.11 The NZAMSC and the DHBAMSTs should consider providing IT or decision support systems that prescribers can use to decide:

- whether to prescribe an antimicrobial or not, particularly when antimicrobials are frequently prescribed for a condition but may not be the best option
- whether alternatives to immediate antimicrobial prescribing may be appropriate (for example, back-up [delayed] prescribing or early review if concerns arise).

1.1.12 The NZAMSC and the DHBAMSTs should consider developing systems and processes to ensure that the following information is provided when a patient’s care is transferred to another care setting:

- information about current or recent antimicrobial use
- information about when a current antimicrobial course should be reviewed
- information about who a patient should contact, and when, if they have concerns about infection.

1.1.13 The NZAMSC and the DHBAMSTs should consider prioritising the monitoring of antimicrobial resistance, to support antimicrobial stewardship across all care settings, taking into account the resources and programmes needed.
1.1.14 PHARMAC’s contracts with suppliers should consider specifying the supply of antimicrobials in pack sizes that correspond to local (where available) and national guidelines on course lengths.

1.1.15 The NZAMSC and the DHBAMSTs, with ESR, should consider evaluating the effectiveness of antimicrobial stewardship interventions by reviewing rates and trends of antimicrobial prescribing and resistance.

**Communication**

1.1.16 The NZAMSC and the DHBAMSTs, with PHARMAC and the Health Quality & Safety Commission (HQSC), should encourage and support prescribers only to prescribe antimicrobials when this is clinically appropriate.

1.1.17 The NZAMSC and the DHBAMSTs, with PHARMAC and the Health Quality & Safety Commission (HQSC), should encourage all healthcare providers across all care settings to work together to support antimicrobial stewardship by:

- communicating and sharing consistent messages about antimicrobial use
- sharing learning and experiences about antimicrobial resistance and stewardship
- referring appropriately between services without raising expectations that antimicrobials will subsequently be prescribed.

1.1.18 The NZAMSC and the DHBAMSTs should consider developing local networks across all care settings to communicate information and share learning on:

- antimicrobial prescribing
- antimicrobial resistance
- patient safety incidents.
1.1.19 The NZAMSC and the DHBAMSTs should consider developing local systems and processes for peer review of prescribing. Encourage an open and transparent culture that allows health professionals to question antimicrobial prescribing practices of colleagues when these are not in line with local (where available) or national guidelines and no reason is documented.

1.1.20 The NZAMSC and the DHBAMSTs should encourage senior health professionals to promote antimicrobial stewardship within their teams, recognising the influence that senior prescribers can have on prescribing practices of colleagues.

1.1.21 The NZAMSC and the DHBAMSTs should raise awareness of current local guidelines on antimicrobial prescribing among all prescribers, providing updates if the guidelines change.

**Laboratory testing**

1.1.22 The NZAMSC and the DHBAMSTs, with ESR, should ensure that laboratory testing and the order in which the susceptibility of organisms to antimicrobials is reported is in line with:

- national and local treatment guidelines
- the choice of antimicrobial in the local formulary
- the priorities of medicines management and antimicrobial stewardship teams.

**Recommendations for prescribers and other healthcare providers**

**Antimicrobial guidelines**

1.1.23 All healthcare providers should support the implementation of local antimicrobial guidelines and recognise their importance for antimicrobial stewardship.
Recommendations for prescribers

Antimicrobial prescribing

1.1.24 When prescribing antimicrobials, prescribers should follow local (where available) or national guidelines on:

- prescribing the shortest effective course
- the most appropriate dose
- route of administration.

1.1.25 When deciding whether or not to prescribe an antimicrobial, take into account the risk of antimicrobial resistance for individual patients and the population as a whole.

1.1.26 When prescribing any antimicrobial, undertake a clinical assessment and document the clinical diagnosis (including symptoms) in the patient’s record and clinical management plan.

1.1.27 For patients in hospital who have suspected infections, take microbiological samples before prescribing an antimicrobial and review the prescription when the results are available.

1.1.28 For patients in primary care who have recurrent or persistent infections, consider taking microbiological samples when prescribing an antimicrobial and review the prescription when the results are available.

1.1.29 For patients who have non-severe infections, consider taking microbiological samples before making a decision about prescribing an antimicrobial, providing it is safe to withhold treatment until the results are available.

1.1.30 Consider point-of-care testing in primary care for patients with suspected lower respiratory tract infections as described in the NICE guideline on pneumonia.
1.1.31 Prescribers should take time to discuss with the patient and/or their family/whānau members or carers (as appropriate):

- the likely nature of the condition
- why prescribing an antimicrobial may not be the best option
- alternative options to prescribing an antimicrobial
- their views on antimicrobials, taking into account their priorities or concerns for their current illness and whether they want or expect an antimicrobial
- the benefits and harms of immediate antimicrobial prescribing
- what they should do if their condition deteriorates (safety netting advice) or they have problems as a result of treatment
- whether they need any written information about their medicines and any possible outcomes.

1.1.32 When an antimicrobial is a treatment option, document in the patient’s records (electronically wherever possible):

- the reason for prescribing, or not prescribing, an antimicrobial
- the plan of care as discussed with the patient, their family/whānau member or carer (as appropriate), including the planned duration of any treatment.

1.1.33 Do not issue an immediate prescription for an antimicrobial to a patient who is likely to have a self-limiting condition.

1.1.34 If immediate antimicrobial prescribing is not the most appropriate option, discuss with the patient and/or their family/whānau members or carers (as appropriate) other options such as:

- self-care with over-the-counter preparations
- back-up (delayed) prescribing
- other non-pharmacological interventions, for example, draining the site of infection.
1.1.35 When a decision to prescribe an antimicrobial has been made, take into account the benefits and harms for an individual patient associated with the particular antimicrobial, including:

- possible interactions with other medicines or any food and drink
- the patient’s other illnesses, for example, the need for dose adjustment in a patient with renal impairment
- any drug allergies (these should be documented in the patient’s record)
- the risk of selection for organisms causing healthcare-associated infections, for example, *C. difficile*.

1.1.36 When prescribing is outside local (where available) or national guidelines, document in the patient’s records the reasons for the decision.

1.1.37 Do not issue repeat prescriptions for antimicrobials unless needed for a particular clinical condition or indication. Avoid issuing repeat prescriptions for longer than 6 months without review and ensure adequate monitoring for individual patients to reduce adverse drug reactions and to check whether continuing an antimicrobial is really needed.

**Prescribing intravenous antimicrobials**

1.1.38 Use an intravenous antimicrobial from the agreed local formulary and in line with local (where available) or national guidelines for a patient who needs an empirical intravenous antimicrobial for a suspected infection but has no confirmed diagnosis.

1.1.39 Consider reviewing intravenous antimicrobial prescriptions at 48–72 hours in all health and care settings (including community and outpatient services). Include response to treatment and microbiological results in any review, to determine if the antimicrobial needs to be continued and, if so, whether it can be switched to an oral antimicrobial.
1.2  **New antimicrobials**

Recommendations for the NZAMSC, DHBAMSTs and PHARMAC

1.2.1  Consider establishing processes for reviewing national horizon scanning to plan for the release of new antimicrobials.

1.2.2  When evaluating a new antimicrobial for inclusion in the formulary, take into account:

- the need for the new antimicrobial
- its clinical effectiveness
- the population in which it will be used
- the specific organisms or conditions for which it will be used
- dose, dose frequency, formulation and route of administration
- likely tolerability and adherence
- any drug interactions, contraindications or cautions
- rates and trends of resistance
- whether use should be restricted and, if so, how use will be monitored
- any additional monitoring needed
- any urgent clinical need for the new antimicrobial
- any plans for introducing the new antimicrobial.

These evaluation features are relevant to PHARMAC’s funding and defunding decisions and complement and are directly or indirectly incorporated into, PHARMAC’s Factors for Consideration decision-making framework [https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration](https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration).

1.2.3  Decision-making groups should assess the benefits and risks of restricting access to a new antimicrobial. This is part of PHARMAC’s decision-making framework.

1.2.4  If access to a new antimicrobial is restricted:
• document the rationale for and the nature of the restriction, and ensure that this information is publicly available
• review the restriction regularly to determine that it is still appropriate.

1.2.5 Ensure that formularies, prescribing guidelines and care pathways are updated when new antimicrobials are approved for use.

1.2.6 Ensure that there is a plan for the timely introduction, adoption and diffusion of a new antimicrobial when this has been recommended for use.

1.2.7 Discuss with the NZAMSC early in the approval process if funding concerns for a new antimicrobial are likely to cause delay in its introduction, adoption and diffusion.

1.2.8 Consider using multiple approaches to support the introduction of a new antimicrobial, including:

• electronic alerts to notify prescribers about the antimicrobial
• prescribing guidance about when and where to use the antimicrobial in practice
• issuing new or updated formulary guidelines and antimicrobial prescribing guidelines
• peer advocacy and advice from other prescribers
• providing education or informal teaching on ward rounds
• shared risk management strategies for antimicrobials that are potentially useful but may be associated with patient safety incidents.

1.2.9 (was 1.2.12) Indicate where prescribers can find accurate, evidence-based and up-to-date information about the new antimicrobial, such as the:

• New Zealand Formulary (NZF)
• New Zealand Formulary for Children (NZFC)
1.2.10 Once a new antimicrobial has been funded and approved for use, organisations should consider ongoing monitoring by:

- conducting an antimicrobial use review (reviewing whether prescribing is appropriate and in line with the diagnosis and national guidelines)
- costing the use of the new antimicrobial
- reviewing the use of non-formulary antimicrobial prescribing
- evaluating prescribing and resistance patterns
- reviewing clinical outcomes such as response to treatment, treatment rates, emerging safety issues, tolerability and length of hospital stay.

2 Implementation: getting started

This section highlights interventions for changing prescribing practice (education and feedback, and information systems to support data collection and feedback), as these could have a big impact on practice and be challenging to implement. The NICE guideline development group identified these with the help of healthcare providers including GPs and pharmacists, commissioners and Guideline Development Group (GDG) members (see section 9.4 of the manual).
2.1 The challenge: changing prescribing practice for antimicrobials

The benefits
Reducing the use of antimicrobials where they are not indicated will:\n
- slow down the emergence of antimicrobial resistance
- ensure that antimicrobials remain an effective treatment for infection
- improve clinical outcomes for the population as a whole
- conserve healthcare resources.

2.1.1 Using education and feedback to change prescribing practice

See recommendations 1.1.3, 1.1.6, 1.1.9, 1.1.10, 1.1.17, 1.1.18, 1.1.19

Education and feedback have been recommended as a way of changing prescribers’ attitudes and supporting antimicrobial stewardship. Potential barriers that may affect prescribers acting on messages about antimicrobial stewardship include:

- the possible risk of adverse outcomes from not treating
- not seeing the direct impact of their prescribing on antimicrobial resistance
- lack of critical evaluation, review and reflection on their own prescribing practice.

DHB, PHARMAC and PHO decision makers could support a change in prescribing practice by:

- allocating resources for education and feedback in their local area
- using governance processes such as audit so that prescribers follow antimicrobial guidelines
- creating an open and transparent culture so that prescribers can question prescribing when this doesn’t follow antimicrobial guidelines
- providing regular updates across the service on individual prescribing, antimicrobial resistance and patient safety incidents

The World Health Organization (2015) Factsheet on antimicrobial resistance
• including antimicrobial stewardship interventions in education programmes which are designed for the setting in which they are to be used
• encouraging prescribers to reflect on their personal practice
• including objectives for antimicrobial stewardship in prescribers’ annual reviews
• signposting prescribers to relevant resources (see further resources for details of resources you may wish to include)
• using the NICE baseline assessment tool to evaluate current practice and plan changes.

**DHB, PHARMAC and PHO decision makers** could support a change in prescribing practice by:

• using contracts to ensure that prescribers have the training and skills for antimicrobial stewardship
• using contracts to ensure that there are programmes for education and feedback on antimicrobial prescribing and resistance.
• ensuring that providers have data about rates and trends of antimicrobial prescribing (for example, from the ESR Surveillance Report on community antimicrobial consumption in New Zealand
• encouraging local learning networks, possibly across clinical areas or services, linking to DHBAMSTs and the NZAMSC

**Those responsible for planning pre- and post-registration training** for prescribers could support a change in prescribing practice by:

• including information about antimicrobial stewardship in training courses
• providing opportunities for prescribers to demonstrate via continuing professional development (CPD)/revalidation that they are following the principles of antimicrobial stewardship.

### 2.1.2 Using information systems to change prescribing practice

See recommendations 1.1.3, 1.1.6, 1.1.10, 1.1.11, 1.1.12

Information systems can help antimicrobial stewardship by capturing data to allow feedback on:
rates and trends of antimicrobial prescribing
rates and trends of antimicrobial resistance
patient use of standard and back-up (delayed) prescriptions.

However the relevant data are not always captured or easily accessible.

The NZAMSC and DHBAMSTs could support the use of information systems to change prescribing practice by:

- supporting the development of a central facility, which presents national and local data on hospital antimicrobial prescribing and resistance in a format that is easy to use
- encouraging the introduction of electronic prescribing where systems are not in place (if a phased approach is needed, this could start with electronic prescribing for antimicrobials)
- commissioning the planning and designing of information systems to support antimicrobial stewardship by establishing working groups (to include IT specialists) across all services; this will need coordination and subgroup working to address differences between the various primary and secondary care services.

DHB and PHO decision makers could support the use of information systems to change prescribing practice by:

- circulating the data they receive about rates and trends of prescribing within their organisation
- using data on rates and trends of prescribing in programmes for educating prescribers about antimicrobial stewardship.

Further resources
NZ

- Antimicrobial resistance prevalence and recent trends:


- Antimicrobial consumption in the community


- Antimicrobial consumption in hospitals


- MoH/MPI strategy for antimicrobial resistance (most up to date version of the New Zealand National Action Plan on Antimicrobial Resistance to be added when available in New Year)

UK

- For primary care, the TARGET antibiotics toolkit designed to support CPD, audit, training and self-assessment for the whole primary care team within a GP practice or out-of-hours setting.

- Further resources are available from NICE to support implementation of this guideline.

- NICE produces indicators annually for use in the Quality and Outcomes Framework (QOF) for the UK. The process for this and the NICE menu are available.

- NICE uptake data about guideline recommendations and quality standard measures are available on the NICE website.

3 Research recommendations

The Guideline Development Group has made the following recommendations for research, based on its review of evidence, to improve NICE guidance and patient care in the future. The Guideline Development Group's full set of research recommendations is detailed in the full guideline.

3.1 Reducing antimicrobial resistance

What interventions, systems and processes are effective and cost effective in reducing antimicrobial resistance without causing harm to patients?
**Recommendation**

Consider undertaking randomised controlled trials to determine whether short versus longer courses of antimicrobials, directly administered (or observed) therapy, continuous versus intermittent therapy and inhaled antimicrobials reduce the emergence of antimicrobial resistance and maintain patient outcomes compared with usual care in the NZ setting.

**3.2 Decision-making**

What interventions, systems and processes are effective and cost effective in changing all healthcare providers’ decision-making and ensuring appropriate antimicrobial stewardship?

**Recommendation**

Consider undertaking randomised controlled trials to determine whether using point-of-care tests in decision-making is clinically and cost effective when prescribing antimicrobials in children, young people and adults presenting with respiratory tract infections.

**4 Other information**

**4.1 Scope and how this guideline was developed**

NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover.
How this guideline was developed

The bpac\textsuperscript{nz} contextualised versions of NICE guidelines provide recommendations about the treatment and care of people with specific diseases and conditions in New Zealand.

The guideline was originally developed by the NICE Internal Clinical Guidelines programme and then contextualised by the bpac\textsuperscript{nz} Guideline Review and Contextualisation Group. The NICE team worked with a group of healthcare professionals (including consultants, GPs and nurses), patients and carers, and technical staff, who reviewed the evidence and drafted the recommendations. The NICE recommendations were finalised after public consultation within the UK. Similarly the bpac\textsuperscript{nz} contextualised version of the NICE guideline were finalised after wide consultation within New Zealand.

The methods and processes for the bpac\textsuperscript{nz} contextualisation of NICE clinical guidelines are described on the bpac\textsuperscript{nz} guidelines website. The NICE guideline was developed using the NICE shore clinical guideline process.

4.2 Related NICE guidance and quality standards

Details are correct at the time of publication of the guideline (August 2015).

Published

- Sepsis: recognitions, diagnosis and early management (2016) NICE guideline NG51
- Medicines optimisation (2015) NICE guideline NG5
- Antibiotics for neonatal infection (2014) NICE quality standard 75
- Infection prevention and control (2014) NICE quality standard 61
- Pneumonia (2014) NICE guideline CG191
- Drug allergy (2014) NICE guideline CG183
- Managing medicines in care homes (2014) NICE guideline SC1
- Surgical site infection (2013) NICE quality standard 49
- Patient group directions (2013) NICE guideline MPG2
• Infection (2012) NICE guideline CG139
• Patient experience in adult NHS services (2012) NICE guideline CG138
• Developing and updating local formularies (2012) NICE guideline MPG1
• Service user experience in adult mental health (2011) NICE guideline CG136
• Medicines adherence (2009) NICE guideline CG76
• Surgical site infection (2008) NICE guideline CG74
• Respiratory tract infections – antibiotic prescribing (2008) NICE guideline CG69

Under development
NICE is developing the following guidance and quality standards:


5 The Guideline Development Group, NICE project team, NICE quality assurance team, New Zealand contextualisation group, and declarations of interest

5.1 Guideline Development Group

Chris Cefai
Consultant in Clinical Microbiology and Infection Control, Betsi Cadwaladr University Health Board, North Wales

Esmita Charani (until 27 November 2014)
Academic Research Pharmacist, the National Centre for Infection Prevention and Management, Imperial College London and Honorary Clinical Pharmacist, Imperial College Healthcare NHS Trust
Lynne Craven
Lay member

Martin Duerden
Sessional/Locum GP, North Wales and Clinical Senior Lecturer, Centre for Health Economics and Medicines Evaluation, Bangor University

Heather Edmonds
Lead Medicines Optimisation and Antimicrobial Pharmacist, Leeds North Clinical Commissioning Group

Alastair Hay (Chair)
Professor of Primary Care and NIHR Research Professor, Centre for Academic Primary Care, School of Social and Community Medicine, University of Bristol; and GP, Concord Medical Centre, Bristol

Philip Howard
Consultant Antimicrobial Pharmacist, Leeds Teaching Hospitals NHS Trust

Sanjay Kalra
Consultant in Trauma and Orthopaedics and Clinical Lead for Infection Control, Royal Liverpool University Hospitals NHS Trust

Tessa Lewis (Vice Chair)
GP and Medical Adviser to All Wales Therapeutics and Toxicology Centre

Kym Lowder
Head of Medicines Management, Integrated Care 24 Limited, Kent

Clodna McNulty
Head of Primary Care Unit, Public Health England

John Morris
Lay member

Sanjay Patel
Consultant in Paediatric Infectious Diseases and Immunology, University Hospital Southampton NHS Foundation Trust
Wendy Thompson
Associate Dentist, Sedbergh Dental Practice, Clinical Supervisor, Blackpool Teaching Hospitals NHS Foundation Trust, Lecturer in Antimicrobial Prescribing, Health Education NE

Susan Walsh
Lay member

5.2  NICE project team

Emma Aaron
Administrator, Medicines and Prescribing Centre, NICE

Anne-Louise Clayton
Editor

Leighton Coombs
Data Analyst, Health Technology Intelligence, NICE (from July to December 2014)

Johanna Hulme
Project Lead and Associate Director, Medicines and Prescribing Centre, NICE

Debra Hunter
Assistant Project Manager, Medicines and Prescribing Centre, NICE (from 29 September 2014)

Dominick Moran
Data Analyst, Costing and Commissioning Implementation, NICE (from July to December 2014)

Greg Moran
Senior Adviser, Medicines and Prescribing Centre, NICE

Roberta Richey
Senior Adviser, Medicines and Prescribing Centre, NICE (from 1 August 2014)
Rebekah Robinson  
Assistant Project Manager, Medicines and Prescribing Centre, NICE (until 26 September 2014)

Erin Whittingham  
Public Involvement Adviser

5.3  **NICE quality assurance team**

Mark Baker  
Clinical Adviser

Christine Carson  
Guideline Lead

Louise Shires  
Guideline Commissioning Manager

Judith Thornton  
Technical Lead

5.4  **NZ Guideline Review and Contextualisation Group**

Scott Metcalfe  
Public Health Physician, Wellington

Alan Moffitt  
General Practitioner, Director, Procare, Auckland

Pauline Norris  
Pharmacist, Professor of Social Pharmacy, University of Otago, Dunedin,

Mark Thomas (Chair)  
Infectious Diseases Physician, University of Auckland, Auckland

Nigel Thompson  
General Practitioner, bpac\textsuperscript{nz}, Dunedin
**Declarations of interests**

The following members of the NICE Guideline Development Group (GDG) made declarations of interests. All other NICE GDG members stated that they had no interests to declare. The conflicts of interest policy (2007) was followed until September 2014, when an updated policy was published.
<table>
<thead>
<tr>
<th>Member</th>
<th>Interest declared</th>
<th>Type of interest</th>
<th>Decision taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alastair Hay (Chair)</td>
<td>Member of Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection. Would like to be aware of evidence gaps and GDG research recommendations that could influence future research programme. Has an interest in the Longitude prize, no financial interests, no involvement in any new antimicrobials.</td>
<td>Personal specific non-financial</td>
<td>Project lead will monitor for any potential conflict. Advice given regarding ensuring that information learnt as part of the NICE guideline process is not shared with other committees/groups etc.</td>
</tr>
<tr>
<td>Alastair Hay (Chair)</td>
<td>No financial conflicts of interest to declare. Lead a group at the University of Bristol conducting research into primary care infections and antimicrobial resistance.</td>
<td>Personal non-financial non-specific</td>
<td>Advice given regarding ensuring that information learnt as part of the NICE guideline process is not shared with other committees/groups etc.</td>
</tr>
<tr>
<td>Esmita Charani</td>
<td>Published in peer reviewed journals.</td>
<td>Personal non-financial non-specific</td>
<td>Advice given regarding ensuring that information learnt as part of the NICE guideline process is not shared with other committees/groups or included within any written articles. Reminded that opinions expressed that may be relevant to the guideline may</td>
</tr>
<tr>
<td>Name</td>
<td>Description</td>
<td>Financial Information</td>
<td>Notes</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>-----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Esmita Charani</td>
<td>Published author on research into antimicrobial stewardship interventions and behaviour change in this field including Cochrane reviews (one ongoing at present). Has also published research on use of mobile health technology to deliver antimicrobial stewardship interventions.</td>
<td>Personal non-financial non-specific</td>
<td>Chair and Project lead will monitor for any potential conflict. Also discussed with the NICE Medicines and Prescribing Centre Programme Director. Advice given regarding ensuring that information learnt as part of the NICE guideline process is not shared with other committees/groups or included within any written articles.</td>
</tr>
<tr>
<td></td>
<td>Salary is funded by the National Institute of Health Research on a grant investigating behaviour change in antimicrobial prescribing.</td>
<td>Non-personal financial non-specific</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Honorary visiting researcher to Haukeland University in Norway where advice on the implementation of the national implementation of an antimicrobial stewardship programme.</td>
<td>Personal non-financial non-specific</td>
<td></td>
</tr>
<tr>
<td>Esmita Charani</td>
<td>Undertaking research at PhD level into antibiotic prescribing behaviours in secondary care.</td>
<td>Personal non-financial non-specific</td>
<td>Chair and Project lead will monitor for any potential conflict. Advice given regarding ensuring that information learnt as part of the NICE guideline process is not shared with other committees/groups or included within any written articles.</td>
</tr>
<tr>
<td><strong>Martin Duerden</strong></td>
<td>Published author in the field of antibiotic prescribing behaviours and antimicrobial stewardship.</td>
<td>of the NICE guideline process is not shared with other committees/groups or included within any written articles.</td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Martin Duerden</strong></td>
<td>Received personal payment (honoraria) plus reimbursement of expenses from Reckitt Benckiser (RB) to speak at 2 meetings in the last 12 months. The subject of the talks was antibiotic use in respiratory infections at each meeting but there was no promotion of products marketed by Reckitt Benckiser in the content.</td>
<td>Personal financial non-specific Advice given regarding ensuring that information learnt as part of the NICE guideline process is not shared with other committees/groups or included within any written articles. Advised not to write for any publication until the guideline has published.</td>
<td></td>
</tr>
<tr>
<td><strong>Martin Duerden</strong></td>
<td>In the last 12 months has also received payment from the publishers of Pulse, GP and Prescriber for writing various articles on prescribing and therapeutics, including antibiotic use.</td>
<td>Personal financial non-specific</td>
<td></td>
</tr>
<tr>
<td><strong>Martin Duerden</strong></td>
<td>Clinical Adviser on Prescribing for the Royal College of General Practitioners but does not receive payment for this.</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td><strong>Martin Duerden</strong></td>
<td>Member of the Global Respiratory Infection Partnership (work declared above with Reckitt Benckiser done in this capacity). Now spoken at 4 meetings in the last 12 months.</td>
<td>Personal financial non-specific</td>
<td></td>
</tr>
<tr>
<td><strong>Martin Duerden</strong></td>
<td>Member of the Paediatric Formulary Committee for the British National Formulary (BNF); payment not received for this.</td>
<td>Personal financial non-specific</td>
<td></td>
</tr>
<tr>
<td><strong>Martin Duerden</strong></td>
<td>On the editorial board of Prescriber (a Wiley publication) which is an unpaid position. Occasionally writes opinion-based editorials and articles for this publication. Receives payments for these.</td>
<td>Personal financial non-specific</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Activity</td>
<td>Financial Details</td>
<td>Comments</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Martin Duerden</td>
<td>Presented at workshops for commissioners introducing the proposed new national Antimicrobial Prescribing Quality Premium and guide commissioners towards resources and best practice – March 2015 in Leeds.</td>
<td>Personal non-specific financial</td>
<td>Advice given regarding ensuring that information learnt as part of the NICE guideline process is not shared with other committees/groups or included within any written articles. Chair and Project lead will monitor for any potential conflict.</td>
</tr>
<tr>
<td></td>
<td>Delivered a session on sharing success and the work that has been done in Leeds. No financial payment was received for presenting.</td>
<td>Personal non-specific financial</td>
<td></td>
</tr>
<tr>
<td>Heather Edmonds</td>
<td>Involved in a Royal College of Nursing published position statement which was sponsored by Pfizer.</td>
<td>Personal non-specific financial</td>
<td>None</td>
</tr>
<tr>
<td>Name</td>
<td>Work Description</td>
<td>Financial Relationship</td>
<td>Advice Given/Commitments</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Rose Gallagher</td>
<td>Paid consultancy work on antibiotics for the pharmaceutical industry: Pfizer (linezolid), Astellas (levofloxacin), AstraZeneca (ceftaroline), Novartis (daptomycin), Gilead (AmBisome).</td>
<td>Personal non-specific financial</td>
<td>Chair and Project lead will monitor for any potential conflict. Advice given regarding ensuring that information learnt as part of the NICE guideline process is not shared with other committees/groups etc.</td>
</tr>
<tr>
<td>Philip Howard</td>
<td>Paid consultancy work with Danone on antimicrobial stewardship.</td>
<td>Non-specific personal financial</td>
<td>Advised not to undertake any further consultancy work in this area during the development of the guideline through to publication.</td>
</tr>
<tr>
<td></td>
<td>Committee member of UK Clinical Pharmacy Association – Pharmacy Infection Network.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Council member of British Infection Association (until May 2013).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Council member of British Society of Antimicrobial Chemotherapy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Published unpaid articles related to antimicrobial stewardship.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Spokesman on Antimicrobials for Royal Pharmaceutical Society.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Philip Howard</td>
<td>Involved in Antimicrobial Resistance Summit at the Royal Pharmaceutical Society in November 2014.</td>
<td>Personal non-specific non-financial</td>
<td>Advised not to undertake any further consultancy work in this area during the development of the guideline through to publication. Advice given regarding</td>
</tr>
</tbody>
</table>
ensuring that information learnt as part of the NICE guideline process is not shared with other committees/groups etc. Chair and Project lead will monitor for any potential conflict.

| Philip Howard | Sponsorship to present work at international conferences (no money received directly):  
|              | – European Association of Hospital Pharmacy (B. Braun 2013 and 2014)  
|              | – European Congress of Clinical Pharmacy and Infectious Diseases (Gilead 2014). Received expenses and conference paid directly to conference.  
|              | Lecture on *Clostridium difficile* multicentre local service evaluation of fidaxomycin. European Advisory Board on pipeline antibiotics (January 2014) funded by Sanofi.  
|              | Lecturing/consultancy about:  
|              | – role of the pharmacist in antimicrobial stewardship  
|              | – antimicrobial medicine specific topics  
|              | – data warehousing  
|              | Advised that as the evidence of the NICE guideline will have been presented he will need to ensure that information he has learnt as being on the GDG is not shared. He agreed and understood.  

| Philip Howard | Personal non-specific financial  
|              | Non-personal non-specific financial
<table>
<thead>
<tr>
<th>Activity</th>
<th>Financial Nature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paid by College of Pharmacy Practice and Education to develop Antimicrobials in Focus (Antimicrobial Stewardship for Community Pharmacists).</td>
<td>Personal non-specific financial</td>
</tr>
<tr>
<td>Research funding from Novartis and Astellas paid directly to an independent audit company to undertake audit. Audits not directly related to antimicrobial stewardship topic.</td>
<td>Non-personal non-specific financial</td>
</tr>
<tr>
<td>Committee member of European Society of Clinical Microbiology and Infectious Diseases, Antimicrobial Stewardship Group (ESGAP). Member of the Department of Health/Public Health England ESPAUR group.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Department of Health ARHAI (Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection) Start Smart then Focus guidance for hospitals group.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>PHE (Public Health England) and RCGP (Royal College of General Practitioners) TARGET AMS for primary care group. PHE (Public Health England)/Department of Health Competencies of Antimicrobial Prescribing and Antimicrobial Stewardship.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Lead a research project on surveying antimicrobial stewardship in hospitals across the world.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Part of a research group developing an antimicrobial guideline application with a European group “Panacea”.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Part of a joint NIHR (National Institute for Health Research) Programme grant AMR themed call on behalf of Leeds and Oxford Universities on antimicrobial allergy.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Antimicrobial resistance round table group (unfunded) with AstraZeneca to help pharmaceutical industry discussion with Government.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Lecture at Clinical Pharmacy Congress (2013 and 2014). Updates provided on respiratory infections in 2013. Updates provided on C. difficile, ESBL and drug</td>
<td>Personal non-specific financial</td>
</tr>
<tr>
<td>Name</td>
<td>Activity</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Philip Howard</td>
<td>Speaker for Royal Pharmaceutical Society at the Royal Colleges Summit on Antimicrobial Resistance. No payment received.</td>
</tr>
<tr>
<td></td>
<td>Introduction of proposed ESPAUR/NHS-England on Quality Premium to reduce antibiotic prescribing.</td>
</tr>
<tr>
<td></td>
<td>Speaker at British Society for Antimicrobial Chemotherapy Antimicrobial Stewardship conference in India.</td>
</tr>
<tr>
<td></td>
<td>British Society of Antimicrobial Chemotherapy (BSAC) workshop on antimicrobial stewardship in India (27–28 November 2014).</td>
</tr>
<tr>
<td>Philip Howard</td>
<td>BSAC workshop on antimicrobial stewardship in Bahrain (24–26 February 2015).</td>
</tr>
<tr>
<td></td>
<td>BSAC round table talk on pharmacy’s role in antimicrobial stewardship.</td>
</tr>
<tr>
<td></td>
<td>Advisory board for new pipeline product, Durata (February 2015). Fees paid into Leeds Teaching Hospitals NHS Trust Charitable Trustees.</td>
</tr>
<tr>
<td>Philip Howard</td>
<td>Advisory boards for: – Durata (Dalbavancin) (February 2015) – Cubist (Tedezolid) (March 2015). Payment to be made to employer (Leeds Teaching Hospitals) for time.</td>
</tr>
<tr>
<td></td>
<td>Attendance at European Association of Hospital Pharmacy conference. B. Braun paid for accommodation, travel paid and attendance. No direct payment received.</td>
</tr>
<tr>
<td>Activity</td>
<td>Nature of Conflict</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Payment to Leeds Teaching Hospital Trust for time.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Speaker at 3 antimicrobial resistance study days for NHS commissioners and a single C. difficile day (March 2015) (NHS England role).</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>GP C. difficile event in Hull (NHS England role).</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Part of a Public Health England project on tailoring antimicrobial programmes.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Speaker at British Society of Antimicrobial Chemotherapy Gulf Antimicrobial Stewardship conference in Bahrain.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>National Sepsis Programme Board (March 2015 onwards).</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>POC CRP testing in Primary Care (Alere) – February 15.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Philip Howard: Associate for the NICE Medicines and Prescribing Centre.</td>
<td>Non-specific non-financial</td>
</tr>
<tr>
<td>Kym Lowder: Stated no conflicts to declare. Spoken at antimicrobial resistance symposia sponsored by public bodies and one by bioMeriux but received no payment. Leads the development of national Public Health England antibiotic and laboratory use guidance for GPs which covers the diagnosis and treatment of urinary tract infections. She has received grants from several publically funded research bodies.</td>
<td>Personal non-specific non-financial</td>
</tr>
<tr>
<td>Name</td>
<td>Activity</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Cliodna McNulty</td>
<td>Lead for e-Bug project across Europe.</td>
</tr>
<tr>
<td></td>
<td>Member of Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection.</td>
</tr>
<tr>
<td></td>
<td>Observer on British Society for Antimicrobial Chemotherapy Council.</td>
</tr>
<tr>
<td></td>
<td>Member of English surveillance programme for antimicrobial utilisation and resistance.</td>
</tr>
<tr>
<td></td>
<td>Lead in the development of Treat Antibiotics Responsibly, Guidance, Education, Tools (TARGET) and promotes the TARGET resources hosted by the Royal College of General Practitioners.</td>
</tr>
<tr>
<td></td>
<td>Involved in judging the Longitude prize.</td>
</tr>
<tr>
<td></td>
<td>Attended advisory board meeting organised by Hayward Medical Communications on 16/05/14 to discuss procalcitonin: event organised on behalf of</td>
</tr>
<tr>
<td>Name</td>
<td>Details</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Sanjay Patel</td>
<td>Has written a paper on antimicrobial stewardship.</td>
</tr>
<tr>
<td>Sanjay Patel</td>
<td>Author of book chapter about antimicrobial stewardship in paediatric care. Manuscript prepared April 2015 for Oxford University Press.</td>
</tr>
<tr>
<td>Sanjay Patel</td>
<td>Has had a relevant journal article published.</td>
</tr>
<tr>
<td>Wendy Thompson</td>
<td>Lectured to foundation dentists on antimicrobial prescribing in general dental practice. Guidance to Foundation Dentists in Health Education (North East).</td>
</tr>
<tr>
<td>Wendy Thompson</td>
<td>Lecturer on antimicrobial stewardship prescribing at a Local Professional Network event in Chester in November and sponsored by Colgate.</td>
</tr>
</tbody>
</table>
| Wendy Thompson       | Offer received from Leeds University re PhD sponsored financially by Leeds University entitled educating patients about dental treatment rather than antibiotic prescriptions for dental pain. | Personal non-specific financial | Advice given regarding ensuring that information learnt as part of the NICE guideline process is not
Lecturing at British Dental Association Conference on prescribing standards and guidance – May 2016 – no financial gain. | Personal non-specific non-financial | shared with other committees/groups or included within any written articles.

Wendy Thompson | Represents and works for organisations that support people with faulty immune systems. Antimicrobials are life-saving medicines for these patients. | Personal non-specific non-financial | None

Susan Walsh | Primary Immunodeficiency UK (PID UK) received 2 grants from CSL Behring in the last 12 months. They were unrestricted and were unrelated to antimicrobials. | Non-personal non-specific financial | None

Susan Walsh | Restricted grant from Biotest UK Ltd to PID UK. Sponsorship from Bio Products Laboratory Ltd to attend a European Society for Immunodeficiencies conference – unrelated to antimicrobial stewardship. | Non-personal non-specific financial | None

Susan Walsh | Appointment as community member of NICE Public Health Advisory Committee: guideline on ‘Antimicrobial resistance: changing risk-related behaviours in the general population’ (confirmed 27 January 2015). | Non-personal non-specific financial | None

5.5.1 Declarations of interests

5.5.2 The following members of the Guideline Review and Contextualisation Group (GRCG) made declarations of interests.

<table>
<thead>
<tr>
<th>Member</th>
<th>Interest declared</th>
<th>Type of interest</th>
<th>Decision taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Thomas</td>
<td>Investigator in a HRC and ADHB funded study of the impact of smartphone app (SCRIPT) on the level of adherence of antimicrobial prescribing to Auckland City Hospital antimicrobial guidelines since 2015.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Position/Role</td>
<td>Conflict of Interest</td>
<td>Additional Information</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>Scott Metcalfe</td>
<td>Employed by PHARMAC (NZ Pharmaceutical Management Agency), a crown entity directly affected by the contextualised guideline. Dr Metcalfe undertook this contextualisation work explicitly in a private capacity as a public health medicine specialist, without recourse to PHARMAC and his views do not represent PHARMAC.</td>
<td>Personal, non-financial, non-specific.</td>
<td>Chair and project lead will monitor for any potential conflict.</td>
</tr>
<tr>
<td>Scott Metcalfe</td>
<td>Observer(without formal group consensus decision-making role) - Joint NZ Ministry of Health /Ministry for Primary Industries New Zealand Antimicrobial Resistance Action Planning Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scott Metcalfe</td>
<td>Member, NZ College of Public Health Medicine (NZPHM) Policy Committee. The NZCPHM is a NZ health professional organisation affected by the contextualised guideline, advocates for public health, and has a formal stance on the control of AMR.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scott Metcalfe</td>
<td>Board Member, NZ Medical Association (NZMA). The NZMA is a NZ health professional organisation affected by the contextualised guideline, advocates for public health, and has a formal stance on the control of AMR.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scott Metcalfe</td>
<td>Executive Board Member, OraTaiao: The New Zealand Climate and Health Council</td>
<td>Personal, non-financial, non-specific.</td>
<td>Chair and project lead will monitor for any potential conflict.</td>
</tr>
<tr>
<td>Alan Moffitt</td>
<td>Clinical Director of ProCare PHO &amp; Management Services Organisation</td>
<td>Personal, non-financial, non-specific.</td>
<td>Chair and project lead will monitor for any potential conflict.</td>
</tr>
<tr>
<td>Alan Moffitt</td>
<td>Chair Auckland/Waitemata Diabetes Service Level Alliance Team</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alan Moffitt</td>
<td>Was Chair now Member – Metropolitan Auckland Clinical Governance Forum. Has input to clinical pathways and guidance for PHOs &amp; DHBs in Auckland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alan Moffitt</td>
<td>Member Counties Manukau health Alliance leadership Team. Decision-making forum for PHO &amp; DHB activity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alan Moffitt</td>
<td>Member Auckland-Waitemata Alliance Leadership team. Decision-making forum for PHO &amp; DHB activity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alan Moffitt</td>
<td>Member Primary Care Expert Advisory Group – NZ Health Quality and Safety Commission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pauline Norris</td>
<td>Published author of research in the field of antibiotic consumption in the community</td>
<td>Personal, non-financial, non-specific.</td>
<td>Chair and project lead will monitor for any potential conflict.</td>
</tr>
<tr>
<td>Nigel Thompson</td>
<td>No conflicts to declare</td>
<td>Nil</td>
<td></td>
</tr>
<tr>
<td>Arlo Upton</td>
<td>Work for Healthscope NZ which is a publicly listed company (private laboratories)</td>
<td>Personal, financial, non-specific.</td>
<td>Chair and project lead will monitor for any potential conflict.</td>
</tr>
<tr>
<td>Arlo Upton</td>
<td>Owns shares in BLIS Technologies Limited (produces probiotic for GAS throat infections)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
About this guideline

NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions.

NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover.

This guideline was developed by the Medicines and Prescribing Centre at NICE. The Centre worked with a Guideline Development Group, comprising healthcare professionals (including consultants, GPs and nurses), patients and carers, and technical staff, which reviewed the evidence and drafted the recommendations. The recommendations were finalised after public consultation.

This guideline was developed using the methods described in the integrated process statement, the interim methods guide for developing medicines practice guidelines and Developing NICE guidelines: the manual (2014).

NICE produces guidance, standards and information on commissioning and providing high-quality healthcare, social care, and public health services. We have agreements to provide certain NICE services to Wales, Scotland and Northern Ireland. Decisions on how NICE guidance and other products apply in those countries are made by ministers in the Welsh government, Scottish government, and Northern Ireland Executive. NICE guidance or other products may include references to organisations or people responsible for commissioning or providing care that may be relevant only to England.

Strength of recommendations

Some recommendations can be made with more certainty than others, depending on the quality of the underpinning evidence. The Guideline Development Group (GDG) makes a recommendation based on the trade-off between the benefits and harms of an intervention, taking into account the quality of the underpinning evidence. The wording used in the recommendations in this guideline denotes the certainty with which the recommendation is made (the strength of the recommendation).
For all recommendations, NICE expects that there is discussion with the person about the risks and benefits of the interventions, and their values and preferences. This discussion aims to help them to reach a fully informed decision (see also Person-centred care).

**Interventions that must (or must not) be used**

We usually use ‘must’ or ‘must not’ only if there is a legal duty to apply the recommendation. Occasionally we use ‘must’ (or ‘must not’) if the consequences of not following the recommendation could be extremely serious or potentially life threatening.

**Interventions that should (or should not) be used – a ‘strong’ recommendation**

We use ‘offer’ (and similar words such as ‘refer’ or ‘advise’) when we are confident that, for the majority of people, an intervention will do more good than harm, and be cost effective. We use similar forms of words (for example, ‘Do not offer…’) when we are confident that an intervention will not be of benefit for most people.

**Interventions that could be used**

We use ‘consider’ when we are confident that an intervention will do more good than harm for most people, and be cost effective, but other options may be similarly cost effective. The choice of intervention, and whether or not to have the intervention at all, is more likely to depend on the patient’s values and preferences than for a strong recommendation, and so the health professionals should spend more time considering and discussing the options with the person.

**Other versions of this guideline**

The full guideline, [antimicrobial stewardship: systems and processes for effective antimicrobial medicine use](https://www.nice.org.uk/quality(std)/3734) contains details of the methods and evidence used to develop the guideline. It is published by the Medicines and Prescribing Centre at NICE.

We have produced [information for the public](https://www.nice.org.uk/quality(std)/3734) about this guideline.
**Implementation**

Implementation tools and resources to help you put the guideline into practice are also available.

**Your responsibility**

This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summaries of product characteristics of any drugs.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

**Copyright**

© National Institute for Health and Care Excellence 2015. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

ISBN: 978-1-4731-1319-0